Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Réglementation et droit · 29/11/20171 min de lecture
Prospective Grant of Exclusive Patent Commercialization License: N6, A Novel, Broad, Highly Potent HIV-Specific Antibody
Traduction automatique locale · Langue originale de la source
Résumé
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent commercialization license to GlaxoSmithKline Intellectual Property Development Ltd (GSK) located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Langue originale de la source: Federal Register — All DocumentsOuvrir le communiqué original →